The Laboratory for Research and Development in the Genetic Institute at Tel-Aviv Sourasky Medical Center was established to conduct basic science research and to develop new methodologies and applications for genetic diagnosis and possible therapy of genetic diseases and cancer.
The laboratory is using a comprehensive genetic research approach involving new high-tech methodologies.

We focus on two major issues:

1. Identification of genes involved in cancer formation and progression

2. The role of major environmental hazardous, such as nicotine, on human health.

In cancer research, we aim to identify genes and genetic pathways important for tumorigenesis that may be used as diagnostic markers. Specifically, we are studying prostate cancer and bone and soft tissue tumors.
The projects in the lab include identification of quantitative genetic alterations (amplifications, deletions, duplication) in tumors using array-based CGH and Spectral Karyotyping, analysis of gene expression profiles of cancer tissues, using microarrays, and the identification of new mutations and single nucleotide polymorphisms (SNPs) in genes that may be associated with increased risk for cancer, using dHPLC.
The second main research is on the role of the family of neuronal nicotinic receptors, the key human proteins that connect nicotine and its effects on human disorders. We are studying models with deficiency in these genes using the Telemetry physiological research system, as well as multiple genetic and protein techniques.

More specifically, we are studying the role of these genes in common brain disorders, such as epilepsy, in inflammation and temperature control.

For more information please contact Prof. Avi Orr-Urtreger, MD/PhD, Director of the Genetic Institute

aviorr@tasmc.health.gov.il